YAFI Online Programming // Disease State Management and Drug Therapy

PSA (Prostate Specific Advancements)

Understanding Supportive Care, Updated Guidelines, and Novel Medications

Educational Objectives

After participating in this activity, pharmacists will be able to:

  • DESCRIBE current diagnostic methods and classifications for prostate cancer
  • LIST new treatment options for prostate cancer and their monitoring parameters
  • RECALL supportive care interventions for patients experiencing troubling symptoms
  • APPLY the principles of motivational interviewing to patients who have prostate cancer to improve medication adherence

After participating in this activity pharmacy technicians will be able to:

  • RECALL common symptoms of prostate cancer and the typical medications used to treat them
  • IDENTIFY medications that are typically appropriate for symptom management in patients with prostate cancer
  • RECOGNIZE when to refer patients to the pharmacist for recommendations

Session Offered

Release Date: May 1, 2020

Expiration Date: May 1, 2022

Course Fee


Session Codes


20YC39-TFB39-Pharmacy Technician

Accreditation Hours

2.0 hours of CE


Prostate cancer is the most common cancer diagnosed in men. Most men are diagnosed with localized prostate cancer. Treatment varies depending on men's risk factors for developing advanced disease. Recently the classification for localized prostate cancer has been updated to categorize patients who may benefit from additional diagnostic testing and treatment options. Surgery, radiation, and androgen deprivation therapy (i.e., hormonal therapy) are the mainstays of localized prostate cancer treatment. Those with very high risk disease now may also benefit from the addition of chemotherapy with docetaxel. Men whose cancer has progressed also have new therapeutic options. Second-generation antiandrogens including apalutamide, darolutamide, and enzalutamide can be used for non-metastatic castrate-resistant prostate cancer. In those with newly diagnosed metastatic disease, apalutamide and enzalutamide are also now options. To date, targeted therapy has not been useful in prostate cancer. However, a small number of patients may have mutations that will respond to targeted therapy. Olaparib may now be considered for a select group of patients with DNA repair gene mutations. These new treatment advancements in prostate cancer require the pharmacy team to be familiar with common side effects and methods to mitigate them. Appropriate monitoring and supportive care therapies that facilitate patient adherence and tolerance of therapy should be included as part of the continuum of care.

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission


Grant funding: Astellas Pharma Glob

Cost: Free

Initial Release Date: May 1, 2020
Expiration Date: May 1, 2022

To obtain CPE credit, visit the UConn Online CE Center

Use your NABP E-profile ID and the session code 20YC58-VXT84 for pharmacists or 20YC58-HBC49 for pharmacy technicians to access the online quiz and evaluation.

First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.

For questions concerning the online CPE activities, email joanne.nault@uconn.edu


Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, Associate Clinical Professor, University of Connecticut (UConn) School of Pharmacy and UConn Health Neag Cancer Center

Faculty Disclosure

The author has no actual or potential conflicts of interest associated with this article.

Disclosure of Discussions of Off-label and Investigational Drug Use

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



Prostate cancer is the most common cancer diagnosed in men and the second leading cause of cancer-related deaths.1 It arises in the prostate gland, which is a solid, round, heart-shaped organ positioned between the bladder and urogenital diaphragm. It is comprised of secretory cells. Its main function is secreting fluid that nourishes and protects sperm. Normal growth and differentiation of the prostate gland depends on presence of androgens, specifically dihydrotestosterone.2 Both the testes and adrenal glands are major sources of circulating androgens, such as dihydrotestosterone.


Full List of References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer. 2019;69:7-34.
2. Norris LB, Kolesar JM. Prostate Cancer. In: DiPiro T, Matzke GR, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York: McGraw-Hill, 2017.
3. Mayo Clinic Staff. (2019, April 17). Prostate cancer. Available at
https://www.mayoclinic.org/diseases-conditions/prostatecancer/symptoms-causes/syc-20353087. Accessed April 29, 2020.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer. Version 1.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed April 1, 2020.
5. Descotes J-L. Diagnosis of prostate cancer. Asian J Urol. 2019;6:129-126.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer Early Detection. Version 2.2019. Available at https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed April 1, 2020.
7. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 2010;28(25):3951-3957.
8. Patel HD, Chalfin JH, Carter HB. Improving prostate cancer screening and diagnosis: health policy and biomarkers beyond PSA. JAMA Oncol. 2016;2:867-868.
9. Epstein JI. An update of the Gleason grading system. J Urol. 2010;183(2):433.
10. Amin MB, Greene FL, Edge S, et al., eds. AJCC Cancer Staging Manual (8th Edition). New York: Springer; 2017.
11. Thakur A, Aishwarya R, Ghosh A, et al. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother. 2018;101:211-218.
12. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.
13. Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27:868-874.
14. Parikh RR, Saraiay B. Multidisciplinary care in high-risk prostate cancer is the new standard of care. J Clin Oncol. 2020;37(14):1143-1147.
15. Rosenthal SA, Hu C, Sartor O, et al. Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG Oncology RTOG 0521 trial. J Clin Oncol. 2019;37:1159-1168.
16. Rice MA, Malhorta SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019; https://doi.org/10.3389/fonc.2019.00801.
17. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367:11871197.
18. Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. (2019) 20:556-569.
19. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408-1418.
20. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246.
21. Chi KM, Argarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13-24.
22. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121-131.
23. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974-2986.
24. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer with a germline BRCA1/2 mutation. J Clin Oncol. 2014;33:244-250.
25. Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2018;19:975-986.
26. U.S. Food and Drug Administration. Drugs@FDA: FDA_Approved Drugs. Available at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020449. Accessed April 11, 2020.
27. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at https://www.wolterskluwercdi.com/lexicomp-online/. Accessed April 1, 2020.
28. Erleada [package insert]. Horsham PA: Janssen Products LP; 2019.
29. Xtandi [package insert]. Northbrook, IL: Astellas Pharma US; 2019.
30. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available at https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed April 12, 2020.
31. Nubeqa [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.;2019.
32. Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP;2019.
33. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Survivorship. Version 1.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/survivorshi p.pdf. Accessed April 1, 2020.
34. Wibowo E, Wassersug RJ, Robinson JW, et al. An educational program to help patients manage androgen deprivation therapy side effects: feasibility, acceptability, and preliminary outcomes. Am J Mens Health. 2020;14(1):1557988319898991. doi: 10.1177/1557988319898991.
35. Spencer JC, Wheeler SB. A systematic review of motivational interviewing interventions in cancer patients and survivors. Patient Educ Couns. 2016l;99(7):1099-1105. doi: 10.1016/j.pec.2016.02.003.
36. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825-836
37. National Osteoporosis Foundation. Learn about Osteoporosis. Available at https://www.nof.org/patients/. Accessed April 12, 2020.
38. World Health Organisation. WHO Fracture Risk Assessment Tool. Available at https://www.sheffield.ac.uk/FRAX/. Accessed April 12, 2020.
39. Patil T, Bernanrd B. Complications of androgen deprivation therapy in men with prostate cancer. Oncol (Williston Park). 2018;32:470-474.